Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Longevity peptides target the core biological mechanisms of aging — telomere maintenance, mitochondrial function, gene-expression regulation, sleep architecture, and cellular senescence. This guide covers seven of the most researched anti-aging peptides, their mechanisms of action, and what the scientific literature actually shows. Three of them are currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review for the July 23–24, 2026 advisory meeting.
FDA PCAC Advisory Meeting — July 23–24, 2026
Epitalon, MOTS-c, and DSIP are three of the seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 meeting. The PCAC reviews nominations for the 503A Bulk Drug Substances List and makes recommendations — the FDA issues any final rule later. None are confirmed Category 1 yet. Track the regulatory status →
| Peptide | Primary Research Focus | Key Mechanism | PCAC July 2026? |
|---|---|---|---|
| Epitalon | Telomere maintenance, lifespan | Telomerase activation | On docket |
| MOTS-c | Metabolic aging, exercise mimetic | AMPK activation via mitochondrial encoding | On docket |
| GHK-Cu | Skin aging, tissue repair, gene expression | Copper chaperone, 4,000+ gene modulation | — |
| DSIP | Sleep architecture, stress-axis aging | Delta-wave sleep, HPA axis modulation | On docket |
| SS-31 | Mitochondrial bioenergetics | Cardiolipin binding, cristae stabilization | — |
| Humanin | Neuroprotection, metabolic healthspan | STAT3/IGF-1R, Bax inhibition | — |
| Foxo4-DRI | Senolysis — clearance of senescent cells | FOXO4–p53 disruption, selective apoptosis | — |
Telomerase activator — pineal gland peptide
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a natural polypeptide found in the pineal gland. Its primary mode of action is activation of telomerase — the enzyme responsible for maintaining telomere length at chromosome ends. Telomeres shorten with each cell division; critically short telomeres trigger cellular senescence or apoptosis. By re-activating telomerase in somatic cells (which normally express it only at low levels), Epitalon may slow this erosion.
The most extensive research on Epitalon comes from Vladimir Khavinson and Vladimir Anisimov, summarized in their 2010 Ageing Research Reviews paper covering two decades of data. Animal studies demonstrate telomere elongation in somatic cells, activation of telomerase mRNA expression, and lifespan extension of up to 25% in fruit flies and nematodes, with smaller (but significant) effects in mice. Epitalon also normalizes melatonin rhythms — pineal function declines with age, and restoring circadian melatonin production has broad downstream effects on cellular repair, immune function, and sleep quality. Human data is limited to small Russian clinical studies documenting improved lymphocyte telomere length.
Mitochondria-derived metabolic regulator
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — one of the first peptides discovered to be encoded by mitochondrial DNA and act as a systemic hormone. Its primary mechanism involves translocation to the nucleus under metabolic stress, where it activates AMPK and modulates the folate-methionine cycle, driving mitochondrial biogenesis and shifting cellular metabolism toward fat oxidation.
First characterized by Lee et al. in Cell Metabolism (2015), MOTS-c was shown to function as an exercise mimetic — improving insulin sensitivity and reducing obesity in mouse models without changes in food intake. A critical aging connection emerged when researchers found that MOTS-c circulating levels decline significantly with age in both rodents and humans. Administration of MOTS-c to aged mice improved metabolic flexibility, reduced adiposity, and improved physical performance on treadmill tests. More recent studies (Kim et al., 2021) found that centenarians (age 100+) have elevated MOTS-c serum levels relative to elderly controls — consistent with the hypothesis that maintained MOTS-c production is a feature of healthy aging.
Copper tripeptide — master gene regulator
GHK-Cu (Glycine-Histidine-Lysine-Copper) is a copper-chelating tripeptide that occurs naturally in human plasma at concentrations of approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60. The copper-bound form is the biologically active species: it chaperones copper ions into cells and triggers a broad gene-expression program centered on tissue repair, inflammation resolution, and antioxidant defense. Unlike peptides that target a single pathway, GHK-Cu functions as a pleiotropic transcription modulator.
Loren Pickart and Anna Margolina (2018, Biomedicines) compiled evidence that GHK-Cu modulates the expression of over 4,000 human genes — roughly 31% of all genes with known expression patterns — including upregulation of collagen synthesis genes, matrix metalloproteinase inhibitors, superoxide dismutase, and anti-apoptotic factors, alongside downregulation of inflammatory cytokines and cancer-associated pathways. Animal studies demonstrate accelerated wound closure, nerve regeneration, and hair follicle stimulation. Human skin studies show improved dermal thickness, elasticity, and reduction in wrinkle depth with topical and injectable GHK-Cu. It is also one of the most commercially available longevity peptides, with a robust COA testing record across multiple labs.
Delta sleep-inducing peptide — sleep and stress modulator
DSIP (Delta Sleep-Inducing Peptide; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide first isolated from rabbit thalamic venous blood by Schoenenberger and Monnier in 1977. It acts on the hypothalamus and limbic system to promote slow-wave (delta-wave) sleep architecture. Beyond sleep, DSIP modulates the hypothalamic-pituitary-adrenal (HPA) axis — reducing cortisol output under chronic stress conditions — and has been shown to reduce lipid peroxidation, a key marker of oxidative aging.
The sleep-aging connection is well-established: slow-wave sleep declines by roughly 30–40% between age 20 and age 60, with parallel decreases in growth hormone secretion and immune maintenance. DSIP's proposed longevity relevance stems from its ability to normalize sleep architecture in aging models, reduce chronic stress-axis activation (a driver of accelerated aging), and directly reduce oxidative stress markers. Russian clinical studies in the 1990s and early 2000s documented improvements in sleep quality, reduced anxiety, and normalization of circadian cortisol patterns. DSIP is one of seven peptides on the FDA PCAC docket for the July 23–24, 2026 compounding advisory meeting.
Mitochondrial inner membrane stabilizer
SS-31 (Szeto-Schiller peptide 31; D-Arg-2'6'-Dmt-Lys-Phe-NH2) is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane by binding cardiolipin — a phospholipid that is essential for cristae structure and the proper function of electron transport chain complexes. Disruption of cardiolipin oxidation is a key feature of mitochondrial dysfunction in aging; SS-31 protects cardiolipin from oxidation, preserving cristae architecture and respiratory efficiency.
Hazel Szeto's lab (Cornell/Weill Cornell) has published extensively on SS-31, including a landmark 2014 paper in JACC Heart Failure demonstrating that SS-31 reduces ischemia-reperfusion injury in animal models of heart failure by restoring mitochondrial inner membrane potential. In aged rodents, SS-31 improves exercise tolerance and skeletal muscle function. Clinical trials have been conducted in conditions including Barth syndrome (a genetic cardiomyopathy with cardiolipin abnormalities) and heart failure with preserved ejection fraction (HFpEF). The elamipretide phase 2 data in Barth syndrome (TAZPOWER trial, published 2021) showed improvements in mitochondrial function and exercise capacity. As a research peptide, SS-31 is one of the few longevity peptides with meaningful human clinical trial data.
Mitochondria-derived neuroprotective peptide
Humanin is a 21-amino-acid peptide encoded within mitochondrial 16S rRNA — like MOTS-c, it belongs to the emerging class of mitochondria-derived peptides (MDPs). Discovered by Hashimoto et al. in Nature (2001) as a peptide that protects neurons from Alzheimer's-associated toxicity, Humanin acts through multiple pathways: it binds and inhibits the pro-apoptotic protein Bax, activates the STAT3 signaling pathway, and engages insulin/IGF-1 receptor-like mechanisms to improve metabolic and neuroprotective signaling.
Like MOTS-c, circulating Humanin levels decline substantially with age. Kim et al. (2018, Aging) found that Humanin serum levels are significantly higher in centenarians compared to elderly controls and younger individuals, suggesting that sustained Humanin production may be a hallmark of healthy extreme aging. In animal models, Humanin administration improves insulin sensitivity, reduces atherosclerotic plaque formation, protects against diet-induced obesity, and extends lifespan in C. elegans. The neuroprotective evidence is particularly robust: multiple studies have demonstrated protection against beta-amyloid and oxidative stress in neuronal cell lines and mouse Alzheimer's models.
Senolytic peptide — targeted clearance of senescent cells
Foxo4-DRI is a D-amino acid retro-inverso peptide designed to disrupt the interaction between the transcription factor FOXO4 and the tumor suppressor p53 in senescent cells. Senescent cells accumulate with age and secrete a pro-inflammatory mix of cytokines known as the Senescence-Associated Secretory Phenotype (SASP), driving tissue dysfunction and chronic inflammation (inflammaging). Foxo4-DRI interferes with the FOXO4–p53 complex that senescent cells rely on for survival, triggering selective apoptosis specifically in senescent cells while sparing healthy cells that don't rely on this interaction.
Published by Baar et al. in Cell (2017), the seminal study demonstrated that Foxo4-DRI treatment in aged mice reduced several markers of senescent cell burden — including p21 and p16 expression, lipofuscin accumulation, and SASP factor secretion — alongside functional improvements including improved exercise tolerance, renal function, and fur density. Crucially, no off-target toxicity in healthy tissues was observed at the doses tested. Foxo4-DRI represents a fundamentally different strategy from the other peptides in this guide: rather than slowing aging processes in healthy cells, it aims to remove the dysfunctional aged cells that accelerate tissue aging.
Longevity peptides are among the most structurally complex and chemically sensitive research compounds — which makes COA quality especially important. HPLC purity should reach ≥98% for research grade; mass spectrometry should confirm the molecular weight matches the target sequence. Disclosed Labs maintains an independent corpus of verified Certificates of Analysis for Epitalon, MOTS-c, GHK-Cu, SS-31, DSIP, and Humanin, drawn from Janoshik, ILS, Vanguard, Kovera, Freedom Diagnostics, and other labs.
Cat-1 Compounding Tracker
Live status of the 2026 FDA regulatory review
FDA Category 1 Guide
What the 2026 reclassification means for compounding
Find a Prescriber
NPI-verified providers who prescribe compounded peptides
Compounding Pharmacies
503A/503B pharmacies and accreditation status
Compare Peptides
Side-by-side comparison for any two compounds
Are Peptides Safe?
Side effects, risks, and what the research shows
Longevity peptides are a broad class of short-chain amino acid sequences studied for their potential to slow or modulate biological aging processes. They include telomerase-activating peptides (Epitalon), mitochondria-derived peptides (MOTS-c, Humanin, SS-31), copper-chelating peptides that regulate gene expression (GHK-Cu), and sleep-regulating neuropeptides (DSIP). Most longevity peptides are research compounds — they are not FDA-approved treatments for aging, but they are among the most actively studied substances in geroscience.
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a polypeptide extract from the pineal gland. Its primary mechanism of action is activation of telomerase — the enzyme that extends telomeres and counters cellular aging. Key research includes Anisimov and Khavinson (Ageing Research Reviews, 2010), which documented telomere elongation in somatic cells and lifespan extension in animal models, including up to 25% lifespan increase in fruit flies and mice in some studies. Epitalon also modulates melatonin synthesis and circadian rhythm regulation. It is one of seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 meeting.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA, first characterized by Lee et al. in Cell Metabolism (2015). It functions as an exercise mimetic and metabolic regulator by activating AMPK and modulating the folate-methionine cycle in the nucleus. MOTS-c levels decline significantly with age in both rodents and humans, and supplementation in animal studies has been shown to improve insulin sensitivity, reduce obesity, and extend healthspan. It is one of seven peptides under FDA PCAC review for the July 23–24, 2026 compounding advisory meeting.
Longevity peptides target several distinct biological hallmarks of aging: (1) Telomere maintenance — Epitalon activates telomerase, the enzyme that rebuilds telomere caps protecting chromosomes from degradation; (2) Mitochondrial function — MOTS-c, Humanin, and SS-31 support mitochondrial biogenesis, reduce oxidative stress, and stabilize inner membrane integrity (cristae); (3) Gene expression modulation — GHK-Cu regulates over 4,000 genes involved in collagen synthesis, wound repair, inflammation, and antioxidant defense; (4) Sleep and neuroendocrine regulation — DSIP modulates slow-wave sleep architecture and hypothalamic-pituitary-adrenal axis activity, both closely linked to biological aging; (5) Senolysis — Foxo4-DRI selectively induces apoptosis in senescent cells without affecting healthy cells.
Three of the peptides in this guide are on the FDA's Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 advisory meeting: Epitalon, MOTS-c, and DSIP. The PCAC reviews nominations for the 503A Bulk Drug Substances List — the list of substances that licensed 503A compounding pharmacies can legally use. The committee makes recommendations; the FDA issues any final rule later. In April 2026, the FDA separately removed 12 peptides from Category 2 (the significant-safety-risk list), but this does not authorize compounding and does not place them on the Category 1 list. None of the seven peptides on the PCAC docket are confirmed Category 1 yet.
GHK-Cu and Epitalon work through fundamentally different mechanisms. GHK-Cu (Glycine-Histidine-Lysine-Copper) is a tripeptide that chaperones copper ions and acts as a master regulator of gene expression — Pickart and Margolina (2018) documented regulation of over 4,000 genes involved in collagen synthesis, anti-inflammatory pathways, and DNA repair. GHK-Cu is particularly well-studied for skin rejuvenation, wound healing, and nerve repair, and is widely available in both injectable and topical forms. Epitalon targets the telomere-telomerase system more directly — it upregulates telomerase to extend telomere length, which is a more fundamental cellular aging mechanism but one with fewer large-scale human studies than GHK-Cu.
The legal status varies by compound and jurisdiction. In the United States, most longevity peptides — including Epitalon, MOTS-c, and DSIP — are research chemicals sold for laboratory and scientific research purposes. They are not FDA-approved drugs. Some peptides may become eligible for compounding pharmacy dispensing if the FDA adds them to the 503A Bulk Drug Substances List following the PCAC advisory process; a valid prescription from a licensed provider would be required. Consult a regulatory attorney or licensed pharmacist for guidance specific to your situation.
A reliable Certificate of Analysis (COA) for a longevity peptide should include: (1) HPLC purity — look for ≥98% purity for research-grade compounds; (2) Mass spectrometry (MS) confirmation that the molecular weight matches the expected sequence; (3) An identifiable third-party laboratory name that can be independently verified — Janoshik, ILS, Vanguard, Freedom Diagnostics, and Kovera are common research labs in this space; (4) A lot number that matches the product you received. Disclosed Labs maintains a public COA corpus with verified lot numbers — you can check whether a specific lot has been independently tested and what purity was recorded.
Disclosed Labs